|
Established in 2001, Vidacare Corporation is the developer of a broad technology platform that is defining the field of intraosseous (inside the bone) medicine. Products include the EZ-IO Intraosseous Infusion System, the OnControl Bone Marrow System and the OnControl Bone Access System, and applications include vascular access, emergency and disaster medicine, oncology and spinal surgery. Privately held, the company is based in San Antonio, Texas, and its products are marketed in over 50 countries worldwide.〔(Biomed SA Shareholders: Vidacare Corporation )〕 ==History== The intraosseous space was first discovered as a non-collapsible vein in 1922 when C.K. Drinker, MD, of Harvard University examined the circulation of the sternum and confirmed that fluids infused into the bone marrow were quickly absorbed into the central circulation, providing a viable alternative to failed vascular access with traditional methods. However, a reliable, safe and easy method to access this intraosseous space proved elusive and this area of medicine and its opportunities remained largely unexplored. In the mid-1990s, the technologies behind Vidacare's products were developed at the University of Texas Health Science Center, San Antonio, in the Athanasiou laboratory by Kyriacos A. Athanasiou, George Constantinides, and Dan Lanctot. In 2000, Dr. Larry Miller, an emergency physician for over 30 years and one of Vidacare’s founders, set out to develop a technology platform that could be utilized in a broad range of health care settings. These applications included vascular access, bone marrow biopsies and aspirations, regenerative medicine and more. In 2001, Vidacare Corporation was established to bring this technology platform to market. In 2004, Vidacare received its first U.S. Food and Drug Administration (FDA) clearance for the EZ-IO Intraosseous Infusion System – the first battery-powered device to establish immediate vascular access using the IO space.〔(Wall Street Journal presents innovation award to Vidacare )〕 In 2007, Vidacare received additional FDA clearance for the OnControl Bone Marrow System, the first significant improvement to bone marrow procedures in decades.〔(Sales of Vidacare’s bone marrow system expands nationwide )〕 In 2008, the company received FDA clearance for the OnControl Bone Access System for use in spinal surgery procedures. Today, Vidacare’s technology platform is widely recognized as a pioneer in the field of intraosseous medicine. The EZ-IO technology is used in 90 percent of U.S. advanced life support ambulances, over half of U.S. emergency departments, and the U.S. military. It is available in over 50 countries. While IO is well-established as a standard of care for vascular access, it is now being applied in a broader variety of health care settings to both non-emergency and emergency patients.〔Nursing Consortium Releases Consensus Paper on the Use of Intraosseous Vascular Access for Emergent and Non-Emergent Situations ()〕〔Nursing Consortium Releases Consensus Paper on the Use of Intraosseous Vascular Access for Emergent and Non-Emergent Situations ()〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Vidacare Corporation」の詳細全文を読む スポンサード リンク
|